citalopram has been researched along with Adverse Drug Event in 15 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The suicide-related data on citalopram from controlled clinical trials in depression and anxiety disorders were analysed." | 8.83 | Citalopram and suicidality in adult major depression and anxiety disorders. ( Pedersen, AG, 2006) |
| "Patients aged > or =60 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition major depressive disorder were randomized to 12 weeks of double-blind, flexible-dose treatment with escitalopram (10-20 mg/day; N = 130) or placebo (N = 134)." | 5.13 | Escitalopram in the acute treatment of depressed patients aged 60 years or older. ( Bose, A; Gandhi, C; Li, D, 2008) |
| "The suicide-related data on citalopram from controlled clinical trials in depression and anxiety disorders were analysed." | 4.83 | Citalopram and suicidality in adult major depression and anxiety disorders. ( Pedersen, AG, 2006) |
| " The current work leverages genome-wide genetic variation and machine learning to predict response to the antidepressant citalopram using data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial (n = 1257 with both valid genomic and outcome data)." | 4.02 | Inclusion of genetic variants in an ensemble of gradient boosting decision trees does not improve the prediction of citalopram treatment response. ( Beevers, CG; Mallard, TT; McGeary, JE; Shumake, J, 2021) |
| "To determine whether distressing adverse events (DAEs) experienced during initial antidepressant treatment are associated with subsequent DAEs after switching to a second antidepressant." | 2.77 | Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an a ( Castillo, WC; Dusetzina, SB; Ellis, AR; Farley, JF; Gaynes, BN; Hansen, RA; Katz, AJ; Stürmer, T, 2012) |
| "Information on rare adverse effects is often limited when a medication is initially approved for marketing." | 1.56 | Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies. ( Bhasale, A; Fabbri, A; Hooimeyer, A; McEwin, E; Mintzes, B; Mohammad, A; Perry, L, 2020) |
| "The risk of arrhythmia may be increased with concomitant use of other drugs that induce QT prolongation." | 1.51 | Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs. ( Beaussier, H; Bézie, Y; Chastang, A; Corny, J; Lillo-Lelouet, A; Petre, A; Phan Thi, TT; Renet, S, 2019) |
| "As depression is known to be a risk factor for suicide and many antidepressants are P-gp substrates, it has been speculated that inadequate antidepressant treatment response or adverse side effects could be involved." | 1.48 | Post-mortem analysis of suicide victims shows ABCB1 haplotype 1236T-2677T-3435T as a candidate predisposing factor behind adverse drug reactions in females. ( Haukka, J; Palo, JU; Rahikainen, AL; Sajantila, A, 2018) |
| "Phospholipidosis (PLD) is a lysosomal storage disorder induced by compounds, notably cationic amphiphilic drugs, which although reversible interferes with cellular phospholipids." | 1.38 | In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. ( Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fischer, H | 1 |
| Atzpodien, EA | 1 |
| Csato, M | 1 |
| Doessegger, L | 1 |
| Lenz, B | 1 |
| Schmitt, G | 1 |
| Singer, T | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Hooimeyer, A | 1 |
| Bhasale, A | 1 |
| Perry, L | 1 |
| Fabbri, A | 1 |
| Mohammad, A | 1 |
| McEwin, E | 1 |
| Mintzes, B | 1 |
| Shumake, J | 1 |
| Mallard, TT | 1 |
| McGeary, JE | 1 |
| Beevers, CG | 1 |
| Rahikainen, AL | 1 |
| Palo, JU | 1 |
| Haukka, J | 1 |
| Sajantila, A | 1 |
| Chastang, A | 1 |
| Renet, S | 1 |
| Corny, J | 1 |
| Beaussier, H | 1 |
| Petre, A | 1 |
| Lillo-Lelouet, A | 1 |
| Phan Thi, TT | 1 |
| Bézie, Y | 1 |
| Kuo, HW | 1 |
| Liu, SC | 1 |
| Tsou, HH | 1 |
| Liu, SW | 1 |
| Lin, KM | 1 |
| Lu, SC | 1 |
| Hsiao, MC | 1 |
| Hsiao, CF | 1 |
| Liu, CY | 1 |
| Chen, CH | 1 |
| Lu, ML | 1 |
| Shen, WW | 1 |
| Tang, HS | 1 |
| Liu, SI | 1 |
| Chang, LH | 1 |
| Wu, HY | 1 |
| Chang, YS | 1 |
| Yeh, TK | 1 |
| Chen, ACh | 1 |
| Liu, YL | 1 |
| Schuch, LG | 1 |
| Yip, A | 1 |
| Nouri, KF | 1 |
| Gregersen, M | 1 |
| Cason, B | 1 |
| Kukreja, J | 1 |
| Wozniak, C | 1 |
| Brzezinski, M | 1 |
| Clark, SL | 1 |
| Adkins, DE | 1 |
| Aberg, K | 1 |
| Hettema, JM | 1 |
| McClay, JL | 1 |
| Souza, RP | 1 |
| van den Oord, EJ | 1 |
| Katz, AJ | 1 |
| Dusetzina, SB | 1 |
| Farley, JF | 1 |
| Ellis, AR | 1 |
| Gaynes, BN | 1 |
| Castillo, WC | 1 |
| Stürmer, T | 1 |
| Hansen, RA | 1 |
| Primeau, M | 1 |
| Pomeraniec, F | 1 |
| Wallace, DM | 1 |
| Pedersen, AG | 1 |
| Vari, G | 1 |
| Beckson, M | 1 |
| Bose, A | 1 |
| Li, D | 1 |
| Gandhi, C | 1 |
1 review available for citalopram and Adverse Drug Event
| Article | Year |
|---|---|
Citalopram and suicidality in adult major depression and anxiety disorders.
Topics: Adverse Drug Reaction Reporting Systems; Antidepressive Agents, Second-Generation; Anxiety Disorders | 2006 |
3 trials available for citalopram and Adverse Drug Event
| Article | Year |
|---|---|
Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.
Topics: Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Drug-Related Side Effects | 2012 |
Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an a
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram | 2012 |
Escitalopram in the acute treatment of depressed patients aged 60 years or older.
Topics: Age Factors; Aged; Analysis of Variance; Citalopram; Depressive Disorder; Double-Blind Method; Drug- | 2008 |
11 other studies available for citalopram and Adverse Drug Event
| Article | Year |
|---|---|
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies.
Topics: Australia; Canada; Citalopram; Databases, Factual; Drug and Narcotic Control; Drug-Related Side Effe | 2020 |
Inclusion of genetic variants in an ensemble of gradient boosting decision trees does not improve the prediction of citalopram treatment response.
Topics: Antidepressive Agents; Area Under Curve; Biomarkers, Pharmacological; Citalopram; Databases, Factual | 2021 |
Post-mortem analysis of suicide victims shows ABCB1 haplotype 1236T-2677T-3435T as a candidate predisposing factor behind adverse drug reactions in females.
Topics: Adult; Alleles; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; Autopsy; Cital | 2018 |
Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antipsychotic Agents; Arrhythmias, Cardiac; Citalopram; Drug In | 2019 |
CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions.
Topics: Antidepressive Agents; Citalopram; Cytochrome P-450 CYP1A2; Depressive Disorder, Major; Drug-Related | 2013 |
Serotonin Syndrome Following an Uncomplicated Orthopedic Surgery in a Patient With Post-Traumatic Stress Disorder.
Topics: Adult; Citalopram; Diskectomy; Drug-Related Side Effects and Adverse Reactions; Humans; Low Back Pai | 2016 |
Serotonin toxicity in aripiprazole augmentation.
Topics: Antipsychotic Agents; Aripiprazole; Citalopram; Cyproheptadine; Drug Synergism; Drug-Related Side Ef | 2012 |
Escitalopram-associated serotonin toxicity.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Drug-Related Side Effects a | 2007 |